



# 15<sup>th</sup> Legal Affairs CONFERENCE

26-27 MARCH 2019  
 HOTEL OKURA, AMSTERDAM

## TUESDAY 26 MARCH

18:00  
 19:00 REGISTRATION AND WELCOME COCKTAIL



19:00  
 20:00 **SESSION I - THE EUROPEAN PATENT SYSTEM AND PATENT QUALITY**



**CHAIR**  
**Jules Fabre**, Senior Counsel, European IP & Regulatory Litigation, Teva



**PANELLISTS**  
**Sjoerd Hoekstra**, Director Patent Examination, EPO  
**Imre Gonda**, Head of IP, Gedeon Richter  
**Karin Pramberger**, IP Director, Polpharma Group

Questions & answers

20:00  
 22:00 NETWORKING DINNER WITH SPEAKERS AND LEGAL EXPERTS

## WEDNESDAY 27 MARCH

09:00 WELCOME NETWORKING COFFEE



09:30 OPENING ADDRESS **Adrian van den Hoven**  
 Director General, Medicines for Europe



09:40 **SESSION II - A HIGH LEVEL DISCUSSION ON: "THE PHARMA SECTOR INQUIRY: 10 YEARS ON & THE FUTURE"**



**CHAIR**  
**Andreas Schillack**, Head Legal Europe, Sandoz International GmbH



**PANELLISTS**


- **Kees Schillemans**, Partner, Allen & Overy LLP
- **Agnieszka Deeg-Tyburnska**, Legal Director, Polpharma Group
- **Tomos Shillingford**, Associate General Counsel IP, Insud Pharma
- **George Moore**, Assistant General Counsel-Europe, Australia & Asia, Mylan

Questions & answers

# 15<sup>th</sup> Legal Affairs CONFERENCE

26-27 MARCH 2019  
 HOTEL OKURA, AMSTERDAM



	10:30	NETWORKING COFFEE BREAK
	11:00	SESSION III - 45-MINUTE ROUNDTABLE DISCUSSIONS
<p>Delegates may attend two of the discussion tables below for a period of 45 minutes per session:</p> <ol style="list-style-type: none"> <li>1. <b>The 505(b)(2) approval pathway system in the US</b>            Moderator: <b>Jeffrey Francer</b>, Senior VP &amp; GC, Association for Accessible Medicines (AAM)            Co-moderator: <b>Kenneth V. Phelps</b>, President and Founder, Camargo Pharmaceutical Services</li> <li>2. <b>Second medical use patents</b>            Moderator: <b>Ignace Vernimme</b>, Partner, Stibbe</li> <li>3. <b>The legal impact of non-compliance with FMD</b>            Moderator: <b>György Thaler</b>, Development Director, Gedeon Richter            Co-moderator: <b>Johan Verhaeghe</b>, National Policy Liaison, Medicines for Europe</li> <li>4. <b>Policies to stimulate competition</b>            Moderator: <b>Harald Mische</b>, Official DG Competition, European Commission</li> <li>5. <b>Confidentiality of data</b>            Co-moderator: <b>Vincenzo Salvatore</b>, Of Counsel, Leader of the Healthcare and Life sciences Focus Team, BonelliErede            Co-moderator: <b>Miguel Vidal-Quadras Trias de Bes</b>, Legal Expert, AESEG</li> <li>6. <b>The concept of plausibility</b>            Co-moderator: <b>Tomos Shillingford</b>, Associate General Counsel IP, Insud Pharma            Co-moderator: <b>Sascha Stolzenberger</b>, Director of Biotech IP, Gedeon Richter Pharma GmbH</li> <li>7. <b>New technologies in pharma</b>            Co-moderator: <b>George Moore</b>, Assistant General Counsel-Europe, Australia &amp; Asia, Mylan            Co-moderator: <b>Kristof Roox</b>, Partner, Crowell &amp; Moring</li> <li>8. <b>The new Trade Secrets regime</b>            Moderator: <b>Benjamin May</b>, Partner, ARAMIS Société d'Avocats</li> </ol>		
	12:40	NETWORKING BUFFET LUNCH

# 15<sup>th</sup> Legal Affairs CONFERENCE

26-27 MARCH 2019  
HOTEL OKURA, AMSTERDAM



	14:00	<b>SESSION IV - THE SPC MANUFACTURING WAIVER: WHERE DO WE STAND?</b>
<p>  <b>CHAIR</b>  <b>Kristof Roox</b>, Partner, Crowell &amp; Moring         </p> <p>  <b>PANELLISTS</b> <ul style="list-style-type: none"> <li>• <b>Alfonso Calles-Sánchez</b>, Administrator, DG Grow, European Commission</li> <li>• <b>Beatriz Díaz de Escauriaza</b>, Senior IP Counsel, Insud Pharma</li> <li>• <b>Corinna Sundermann</b>, Senior Vice President Intellectual Property, Fresenius Kabi</li> </ul> </p> <p>Questions &amp; answers</p>		
	14:50	<b>SESSION V – THE SPC REGULATION: THE LEGAL REVIEW OF THE MAX PLANCK INSTITUTE</b>
<p>  <b>CHAIR</b>  <b>Kristof Roox</b>, Partner, Crowell &amp; Moring         </p> <p>  <b>PANELLISTS</b> <ul style="list-style-type: none"> <li>• <b>Alfonso Calles-Sánchez</b>, Administrator, DG Grow, European Commission</li> <li>• <b>Roberto Romandini</b>, Max Planck Institute</li> <li>• <b>Karin Pramberger</b>, IP Director, Polpharma Group</li> </ul> </p> <p>Questions &amp; answers</p>		
<p>15:40 NETWORKING COFFEE BREAK</p>		
	16:10	<b>SESSION VI – THE PHARMA INCENTIVES REVIEW: WHAT CAN WE EXPECT NOW?</b>
<p>  <b>CHAIR</b>  <b>Adrian van den Hoven</b>, Director General, Medicines for Europe         </p> <p>  <b>PANELLISTS</b> <ul style="list-style-type: none"> <li>• <b>Sven J. R. Bostyn</b>, Associate Professor of Biomedical Innovation Law, University of Copenhagen</li> <li>• <b>Marcel van Raaij</b>, Director Pharmaceutical Affairs &amp; Medical Technology, Dutch Ministry of Health, Welfare and Sports</li> <li>• <b>George Moore</b>, Assistant General Counsel-Europe, Australia &amp; Asia, Mylan</li> <li>• <b>Ellen 't Hoen</b>, Director, Medicines Law &amp; Policy</li> </ul> </p> <p>Questions &amp; answers</p>		



# 15<sup>th</sup> Legal Affairs CONFERENCE

26-27 MARCH 2019  
HOTEL OKURA, AMSTERDAM



	17:00	SESSION VII – WHAT'S NEW ON BIOSIMILARS: OPPORTUNITIES OR CHALLENGES FOR BIOSIMILAR MEDICINE DEVELOPERS
		<p><b>CHAIR</b>  <b>Floris ten Have</b>, Partner, Stibbe</p> <p><b>PANELLISTS</b></p> <ul style="list-style-type: none"> <li>• <b>Alexander Ott</b>, Senior Patent Attorney, Sandoz/Hexal AG</li> <li>• <b>Kristin Cooklin</b>, Global Head of Patents, Zentiva</li> <li>• <b>Jacek Myszko</b>, Senior Counsel, Sołtysiński Kawecki &amp; Szlęzak</li> <li>• <b>Jeffrey Francer</b>, Senior VP &amp; GC, Association for Accessible Medicines (AAM)</li> </ul> <p>Questions &amp; answers</p>
	17:50	<p>CONCLUDING REMARKS</p> <p><b>Sergio Napolitano</b>, Director Legal and External Affairs, Medicines for Europe</p>
	18:00	END-OF-CONFERENCE COCKTAIL

## GOLD SPONSORS

**crowell** **moring**

**Stibbe**

## CONFERENCE SPONSORS

**Aramis**  
Société d'Avocats

**BarentsKrans**

**BonelliErede**

## MEDIA PARTNERS

**Clarivate  
Analytics**

www.gabionline.net • www.gabi-journal.net  
**GoBi**  
 GENERICS AND  
 BIOSIMILARS  
 INITIATIVE  
*Building trust in cost-effective treatments*

**Generics Bulletin**  
Pharma intelligence | informa

IMS Health & Quintiles are now  
**IQVIA**

**PHARMA  
BOARDROOM**

FOLLOW THE EVENT ON TWITTER #LAC19

For further information <https://www.medicinesforeurope.com/events2019/LAC19/>